An Oklahoma City lab teaching a blood draw to do something doctors couldn't: see a lupus flare coming, up to 12 weeks before it arrives.
A rheumatologist in 2026 opens a lab report and sees a number she didn't used to have. Not inflammation that already happened. Not damage already done. A forecast: this patient's lupus is likely to flare in the next twelve weeks. She can adjust the medication now, while the patient still feels fine. That number comes from Progentec Diagnostics, a 16-person company in downtown Oklahoma City that decided autoimmune disease should be predicted instead of merely chased.
Progentec runs a clinical laboratory and a software stack, which is an unusual pairing until you realize the two halves answer the same question: what is this disease about to do next? Its flagship, the aiSLE DX Flare Risk Index, reads eleven biomarkers out of a single blood sample and turns them into one risk score. Its patient community, LupusCorner, collects the lived experience that lab panels miss. The lab measures the body. The app listens to the person. Both feed the same forecast.
Most of medicine waits for the fire, then grades the damage. Progentec sells the smoke detector.
- The bet, stated plainlyLupus does not progress in a straight line. It flares - the immune system attacks joints, skin, kidneys, sometimes everything at once - and then it quiets down, and nobody can reliably say when the next storm is coming. Patients live on a calendar they cannot read. Doctors manage in the rearview mirror, escalating treatment after the damage shows up rather than before.
The numbers around this are not small. Progentec estimates 25 million Americans live with an autoimmune disease. Lupus ranks as the tenth leading cause of death for women aged 15 to 24. And here is the detail that tends to stop a room: across roughly six decades, only one genuinely new lupus medication earned FDA approval. Diabetes got an industry. Lupus got patience.
The founders' read was that the missing piece wasn't another drug - it was timing. If you could tell a clinician when trouble was coming, the drugs that already exist would work harder, organ damage would drop, and the most expensive part of the disease, the emergency, might never happen.
You cannot manage what you cannot see coming. Lupus has spent sixty years being invisible until it was urgent.
- The gap, in one lineIn 2014, Mohan Purushothaman left a global pricing and market-access role at Alliance Life Sciences. He had spent years - including a stretch at Roche - learning exactly how the industry decides what a treatment is worth. He left to bet that the autoimmune market was mispriced in the most literal sense: it was paying for crises it could have prevented.
He didn't build it alone, and he didn't build it from scratch. The science came out of Oklahoma's own research bench. Dr. Melissa Munroe, who ran serum analyte and biomarker work at the Oklahoma Medical Research Foundation, had spent a career mapping the inflammatory and autoantibody signals that precede autoimmune trouble. She became Progentec's Chief Scientific Officer and Principal Investigator. The company kept collaborating with OMRF scientists rather than walking away from them - an arrangement that later turned OMRF into an investor as well as a research partner.
The bet, reduced to a sentence: take the biomarker science that academia had proven could detect autoimmune signals, wrap it in a real clinical lab and a weighted algorithm, and ship it to the rheumatologist as a number she can act on Monday morning. Less a moonshot than a translation job - and translation is where most good science quietly goes to die.
The hard part was never the discovery. It was turning a research finding into something a busy clinic would actually order.
- The translation problemMohan Purushothaman founds Progentec in Oklahoma City, building on autoimmune biomarker research tied to OMRF.
Researchers refine an algorithm that predicts lupus flares up to three months in advance; early funding rounds support commercialization.
Led by Plains Venture Partners with Stanford, Mayo Clinic, OMRF, OCA Ventures and others - funding the flare-prediction and classification tests.
Progentec acquires the LupusCorner community and app, adding patient-reported outcomes and a real-world evidence engine.
aiSLE DX biomarker tests, including the Flare Risk Index, become orderable by all Mayo Clinic Laboratories clients effective April 25, 2024.
A grant round of roughly $895K supports continued research into digital biomarkers and remote care.
The aiSLE DX Flare Risk Index is a laboratory-developed test. A patient gives a routine blood sample; the lab measures eleven biomarkers; a weighted algorithm converts those measurements into a single risk score for a flare in the next twelve weeks. A positive score is not a vague worry - patients who score positive are nearly five times more likely to flare than those who score negative. That is the kind of separation a clinician can build a treatment plan around.
It does not travel alone. The aiSLE DX Disease Activity Index reads how active the disease is right now, and a classification test helps confirm a lupus diagnosis in the first place. Progentec gives the underlying engines deliberately literal names - LiquidFlareRisk and LiquidDiseaseActivity - as if to insist that the blood itself is doing the talking.
11 biomarkers, one weighted score: the odds of a lupus flare in the coming 12 weeks. Powered by LiquidFlareRisk.
A read on how active the disease is today, to guide ongoing management. Powered by LiquidDiseaseActivity.
Biomarker support for classifying and diagnosing lupus, earlier and with more confidence.
An online community and app where patients learn, track symptoms, and chat with a nurse practitioner - and where real-world data is born.
Four products, one stubborn idea: the disease will tell you what it's about to do, if you build the right ears.
A blood draw is just a blood draw until an algorithm turns it into a heads-up.
- On the aiSLE DX engineA prediction is only worth as much as the gap between being right and being wrong. Progentec's central data point is that separation: a positive flare-risk score corresponds to roughly five times the odds of an actual flare compared with a negative score. For a disease defined by its unpredictability, that is the difference between guessing and managing.
Then there is the company it keeps. The $5M Series A in 2019 wasn't filled out by tourists - Stanford University, Mayo Clinic and the Oklahoma Medical Research Foundation all put money in alongside Plains Venture Partners and OCA Ventures. When the institutions whose names anchor a field also anchor your cap table, the science has cleared a bar that a pitch deck cannot.
The clearest proof of all arrived in 2024, when Mayo Clinic Laboratories began offering Progentec's lupus biomarker tests to its entire client base. A reference lab with Mayo's reputation does not put an outside company's test in its catalog on a hunch. Distribution like that is the moment a startup's claim becomes a clinic's routine.
Mayo Clinic Laboratories doesn't shelve a test on a hunch. That catalog listing is a verdict.
- On the 2024 distribution dealProgentec states its purpose without much decoration: develop diagnostic and care solutions for autoimmune diseases, improve on the tools that already exist, and bring down the cost of care. The vision underneath it is the part worth reading twice - data-driven, proactive healthcare, where a clinician adjusts treatment early enough to limit organ damage rather than document it.
That is also why the company insists on the patient half of the equation. LupusCorner is not a marketing channel dressed as a community. It is how Progentec captures what a lab panel cannot - how a person actually feels, day to day - and folds those patient-reported outcomes back into research. The lab tells you the biology. The patient tells you the truth. A flare-prediction company that listened to only one of them would be missing half the signal.
Proactive care isn't a slogan here. It's the entire reason to measure blood before a patient feels sick.
- The mission, distilledLupus is the proving ground, not the ceiling. Progentec's tagline already reaches past it - proteomics and digital health for lupus, multiple sclerosis and autoimmune disease broadly. The architecture is portable: find the biomarkers that precede a flare, weight them into a score, deliver it through labs clinicians already trust, and let a patient community keep the model honest. What works for lupus is a template for every autoimmune condition that currently announces itself only after the damage starts.
The skeptic's question is fair: a laboratory-developed test is not an FDA-cleared device, the company is small, and prediction in medicine has humbled smarter operations than this one. All true. But the direction of travel is clear, and it runs through one of the most credible reference labs in the country. Small companies that get into Mayo's catalog are not playing pretend.
So return to that rheumatologist in Oklahoma City, or now anywhere a Mayo Clinic Laboratories client draws blood. The number on her screen used to be a record of harm already done. Today it is a heads-up - twelve weeks of runway she did not have before, bought with eleven biomarkers and a stubborn idea that a disease nobody could predict was simply waiting for someone to learn its language. Progentec didn't cure lupus. It did something quieter and, for the patient who never has the flare, just as useful: it changed the calendar.
The flare that gets prevented makes no headline. That silence is the whole product.
- Where we came inLooking for interviews and demos? Search "Progentec Diagnostics" on YouTube or the aiSLE DX flare risk walkthrough for product overviews.